DarioHealth (NASDAQ:DRIO) Price Target Cut to $5.00 by Analysts at Stifel Nicolaus

DarioHealth (NASDAQ:DRIO – Free Report) had its target price trimmed by Stifel Nicolaus to $5.00 in a report issued on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Several other brokerages also recently commented on DRIO. BTIG Research started coverage on DarioHealth in a report on Tuesday, October 27th. They set a “buy” rating and a $6.00 target price on the stock. TD Cowen reduced their price target on DarioHealth from $11.00 to $8.00 and set a “hold” rating on the stock in a research report on Wednesday, August 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of DarioHealth in a research note on Tuesday, October 6th. Finally, Alliance Global Partners began coverage on DarioHealth in a research report on Wednesday, August 19th. They set a “buy” rating and a $12.00 price objective for the company. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $7.75.

View Our Latest Analysis on DRIO

DarioHealth Trading Down 23.6%

Shares of NASDAQ:DRIO traded down $0.39 during mid-day trading on Friday, reaching $1.26. 74,793 shares of the company’s stock were exchanged, compared to its average volume of 86,340. The firm has a market capitalization of $12.35 million, a price-to-earnings ratio of -0.32 and a beta of 1.18. The business’s fifty day moving average price is $5.03 and its 200-day moving average price is $7.32. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.92 and a current ratio of 2.31. DarioHealth has a twelve month low of $1.26 and a twelve month high of $14.77.

DarioHealth (NASDAQ:DRIO – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.95) by $0.22. The company had revenue of $5.31 million for the quarter, compared to analysts’ expectations of $5.21 million. DarioHealth had a negative net margin of 159.85% and a negative return on equity of 55.10%. On average, research analysts predict that DarioHealth will post -2.94 EPS for the current fiscal year.

Hedge Funds Weigh In On DarioHealth

Hedge funds and other institutional investors have recently bought and sold shares of the company. Nantahala Capital Management LLC grew its holdings in DarioHealth by 60.2% during the 3rd quarter. Nantahala Capital Management LLC now owns 978,340 shares of the company’s stock worth $6,746,000 after acquiring an additional 367,649 shares during the period. Commonwealth Equity Services LLC bought a new position in shares of DarioHealth in the 3rd quarter worth about $159,000. Finally, BlackRock Inc. acquired a new position in shares of DarioHealth in the 2nd quarter valued at about $249,000. Institutional investors and hedge funds own 33.39% of the company’s stock.

DarioHealth News Summary

Investors following DRIO have been watching these news items:

  • Positive Sentiment: Third-quarter revenue rose 6% year over year and 3% sequentially to $5.3 million, slightly topping estimates. The reported loss was also narrower than analysts expected, while operating loss fell 15% and operating expenses declined 10% year over year. DarioHealth Q3 results
  • Positive Sentiment: Management said contracted and late-stage annual recurring revenue totaled $13.1 million across more than 180 accounts, with over 80% tied to multi-condition opportunities. It expects revenue growth to accelerate late in 2026 and into 2027 as committed ARR converts, and cited a new New Jersey health-plan customer covering 1.5 million people. DarioHealth Q3 results
  • Neutral Sentiment: Despite the improving operating trends, DarioHealth remains loss-making, and GAAP gross margin edged down to 59% from 60% a year earlier. The forecasted growth depends on converting contracted and late-stage opportunities, so execution and the timing of revenue remain key risks. DarioHealth Q3 results

About DarioHealth

(Get Free Report)

DarioHealth Corp. is a digital health company that develops technology-enabled programs to help people manage chronic and behavioral health conditions. Its offerings combine mobile applications, connected devices, coaching and personalized guidance. The company’s services address conditions including diabetes, hypertension, weight management, musculoskeletal health and behavioral health. Its platform is designed to support individuals as well as employers and health plans seeking to provide digital health programs to their members.

Recommended Stories

Analyst Recommendations for DarioHealth (NASDAQ:DRIO)

Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.